ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 184 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $223,000 | -81.0% | 3,614 | -73.7% | 0.00% | – |
Q3 2018 | $1,174,000 | -53.7% | 13,745 | -37.2% | 0.00% | -100.0% |
Q2 2018 | $2,536,000 | +104.5% | 21,875 | +42.6% | 0.00% | – |
Q1 2018 | $1,240,000 | +88.4% | 15,336 | +36.7% | 0.00% | – |
Q4 2017 | $658,000 | -36.9% | 11,221 | -66.9% | 0.00% | – |
Q1 2017 | $1,043,000 | -27.4% | 33,872 | -21.0% | 0.00% | – |
Q4 2016 | $1,437,000 | +42.3% | 42,878 | +13.0% | 0.00% | – |
Q3 2016 | $1,010,000 | -56.8% | 37,957 | -64.2% | 0.00% | -100.0% |
Q2 2016 | $2,336,000 | -4.2% | 105,942 | +27.6% | 0.00% | 0.0% |
Q1 2016 | $2,438,000 | +137.2% | 83,016 | +166.6% | 0.00% | – |
Q4 2015 | $1,028,000 | -1.2% | 31,136 | -8.4% | 0.00% | – |
Q1 2015 | $1,040,000 | +152.4% | 33,973 | +319.4% | 0.00% | – |
Q4 2014 | $412,000 | -94.5% | 8,100 | -97.5% | 0.00% | -100.0% |
Q3 2013 | $7,432,000 | +23.9% | 324,291 | -4.3% | 0.00% | 0.0% |
Q2 2013 | $5,999,000 | – | 338,791 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |